Literature DB >> 28536267

The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1-RUNX1T1.

Taishi Yonezawa1, Hirotaka Takahashi2, Shiori Shikata1, Xiaoxiao Liu1, Moe Tamura1, Shuhei Asada1, Tsuyoshi Fukushima1, Tomofusa Fukuyama1, Yosuke Tanaka1, Tatsuya Sawasaki2, Toshio Kitamura1, Susumu Goyama3.   

Abstract

RUNX1 is a member of RUNX transcription factors and plays important roles in hematopoiesis. Disruption of RUNX1 activity has been implicated in the development of hematopoietic neoplasms. Chromosomal translocations involving the RUNX1 gene are associated with several types of leukemia, including acute myeloid leukemia driven by a leukemogenic fusion protein RUNX1-RUNX1T1. Previous studies have shown that RUNX1 is an unstable protein and is subjected to proteolytic degradation mediated by the ubiquitin-proteasome pathway. However, the precise mechanisms of RUNX1 ubiquitination have not been fully understood. Furthermore, much less is known about the mechanisms to regulate the stability of RUNX1-RUNX1T1. In this study, we identified several RUNX1-interacting E3 ubiquitin ligases using a novel high-throughput binding assay. Among them, we found that STUB1 bound to RUNX1 and induced its ubiquitination and degradation mainly in the nucleus. Immunofluorescence analyses revealed that the STUB1-induced ubiquitination also promoted nuclear export of RUNX1, which probably contributes to the reduced transcriptional activity of RUNX1 in STUB1-overexpressing cells. STUB1 also induced ubiquitination of RUNX1-RUNX1T1 and down-regulated its expression. Importantly, STUB1 overexpression showed a substantial growth-inhibitory effect in myeloid leukemia cells that harbor RUNX1-RUNX1T1, whereas it showed only a marginal effect in other non-RUNX1-RUNX1T1 leukemia cells and normal human cord blood cells. Taken together, these data suggest that the E3 ubiquitin ligase STUB1 is a negative regulator of both RUNX1 and RUNX1-RUNX1T1. Activation of STUB1 could be a promising therapeutic strategy for RUNX1-RUNX1T1 leukemia.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  E3 ubiquitin ligase; cancer biology; leukemia; nuclear transport; post-translational modification (PTM); protein degradation; transcription factor; ubiquitin ligase; ubiquitin-dependent protease; ubiquitylation (ubiquitination)

Mesh:

Substances:

Year:  2017        PMID: 28536267      PMCID: PMC5535027          DOI: 10.1074/jbc.M117.785675

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development.

Authors:  Ichiro Taniuchi; Motomi Osato; Takeshi Egawa; Mary Jean Sunshine; Suk Chul Bae; Toshihisa Komori; Yoshiaki Ito; Dan R Littman
Journal:  Cell       Date:  2002-11-27       Impact factor: 41.582

2.  Protein degradation: Prime time for PROTACs.

Authors:  Raymond J Deshaies
Journal:  Nat Chem Biol       Date:  2015-09       Impact factor: 15.040

3.  The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.

Authors:  James C Mulloy; Jörg Cammenga; Karen L MacKenzie; Francisco J Berguido; Malcolm A S Moore; Stephen D Nimer
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter.

Authors:  D E Zhang; C J Hetherington; S Meyers; K L Rhoades; C J Larson; H M Chen; S W Hiebert; D G Tenen
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

Review 5.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.

Authors:  Masahiro Ono; Hiroko Yaguchi; Naganari Ohkura; Issay Kitabayashi; Yuko Nagamura; Takashi Nomura; Yoshiki Miyachi; Toshihiko Tsukada; Shimon Sakaguchi
Journal:  Nature       Date:  2007-03-21       Impact factor: 49.962

7.  Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF.

Authors:  J Lu; M Maruyama; M Satake; S C Bae; E Ogawa; H Kagoshima; K Shigesada; Y Ito
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

Review 8.  Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.

Authors:  Susumu Goyama; James C Mulloy
Journal:  Int J Hematol       Date:  2011-05-03       Impact factor: 2.490

Review 9.  Core binding factor at the crossroads: determining the fate of the HSC.

Authors:  Kevin A Link; Fu-Sheng Chou; James C Mulloy
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

10.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Authors:  Jan Krönke; Emma C Fink; Paul W Hollenbach; Kyle J MacBeth; Slater N Hurst; Namrata D Udeshi; Philip P Chamberlain; D R Mani; Hon Wah Man; Anita K Gandhi; Tanya Svinkina; Rebekka K Schneider; Marie McConkey; Marcus Järås; Elizabeth Griffiths; Meir Wetzler; Lars Bullinger; Brian E Cathers; Steven A Carr; Rajesh Chopra; Benjamin L Ebert
Journal:  Nature       Date:  2015-07-01       Impact factor: 49.962

View more
  5 in total

Review 1.  Visualizing ubiquitination in mammalian cells.

Authors:  Sjoerd Jl van Wijk; Simone Fulda; Ivan Dikic; Mike Heilemann
Journal:  EMBO Rep       Date:  2019-01-21       Impact factor: 8.807

2.  VEZF1, destabilized by STUB1, affects cellular growth and metastasis of hepatocellular carcinoma by transcriptionally regulating PAQR4.

Authors:  Xiaobao Shi; Pengfei Zhao; Gang Zhao
Journal:  Cancer Gene Ther       Date:  2022-10-14       Impact factor: 5.854

Review 3.  An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.

Authors:  Sayer Al-Harbi; Mahmoud Aljurf; Mohamad Mohty; Fahad Almohareb; Syed Osman Ali Ahmed
Journal:  Blood Adv       Date:  2020-01-14

Review 4.  RUNX1 Dosage in Development and Cancer.

Authors:  Michael Lie-A-Ling; Renaud Mevel; Rahima Patel; Karen Blyth; Esther Baena; Valerie Kouskoff; Georges Lacaud
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 4.250

5.  STUB1 regulates antiviral RNAi through inducing ubiquitination and degradation of Dicer and AGO2 in mammals.

Authors:  Shumin Zhang; Xuhua Zhang; Yuanyuan Bie; Jing Kong; An Wang; Yang Qiu; Xi Zhou
Journal:  Virol Sin       Date:  2022-05-06       Impact factor: 6.947

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.